Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 6.30
RGDX's Cash to Debt is ranked higher than
66% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. RGDX: 6.30 )
RGDX' s 10-Year Cash to Debt Range
Min: 1.22   Max: No Debt
Current: 6.3

Equity to Asset 0.32
RGDX's Equity to Asset is ranked higher than
50% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. RGDX: 0.32 )
RGDX' s 10-Year Equity to Asset Range
Min: -0.78   Max: 0.62
Current: 0.32

-0.78
0.62
F-Score: 3
Z-Score: -2.42
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -40.13
RGDX's Operating margin (%) is ranked higher than
55% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. RGDX: -40.13 )
RGDX' s 10-Year Operating margin (%) Range
Min: -138.39   Max: 27.64
Current: -40.13

-138.39
27.64
Net-margin (%) -40.51
RGDX's Net-margin (%) is ranked higher than
56% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. RGDX: -40.51 )
RGDX' s 10-Year Net-margin (%) Range
Min: -133.14   Max: 27.86
Current: -40.51

-133.14
27.86
ROE (%) -139.28
RGDX's ROE (%) is ranked lower than
53% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. RGDX: -139.28 )
RGDX' s 10-Year ROE (%) Range
Min: -1439.29   Max: -33.45
Current: -139.28

-1439.29
-33.45
ROA (%) -44.42
RGDX's ROA (%) is ranked higher than
52% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. RGDX: -44.42 )
RGDX' s 10-Year ROA (%) Range
Min: -86.55   Max: 46.3
Current: -44.42

-86.55
46.3
ROC (Joel Greenblatt) (%) -218.54
RGDX's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. RGDX: -218.54 )
RGDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -750.16   Max: 206.11
Current: -218.54

-750.16
206.11
Revenue Growth (%) -21.10
RGDX's Revenue Growth (%) is ranked higher than
57% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. RGDX: -21.10 )
RGDX' s 10-Year Revenue Growth (%) Range
Min: -32.5   Max: 19
Current: -21.1

-32.5
19
EBITDA Growth (%) -2.90
RGDX's EBITDA Growth (%) is ranked higher than
68% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. RGDX: -2.90 )
RGDX' s 10-Year EBITDA Growth (%) Range
Min: -30.9   Max: 23
Current: -2.9

-30.9
23
EPS Growth (%) -2.60
RGDX's EPS Growth (%) is ranked higher than
69% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. RGDX: -2.60 )
RGDX' s 10-Year EPS Growth (%) Range
Min: -31.4   Max: -2.6
Current: -2.6

-31.4
-2.6
» RGDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RGDX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.90
RGDX's P/B is ranked lower than
71% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. RGDX: 6.90 )
RGDX' s 10-Year P/B Range
Min: 1.79   Max: 36.7
Current: 6.9

1.79
36.7
P/S 2.00
RGDX's P/S is ranked higher than
70% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. RGDX: 2.00 )
RGDX' s 10-Year P/S Range
Min: 0.88   Max: 4.34
Current: 2

0.88
4.34
EV-to-EBIT 13.70
RGDX's EV-to-EBIT is ranked higher than
72% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. RGDX: 13.70 )
RGDX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 13.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 58.00
RGDX's Price/Net Current Asset Value is ranked lower than
89% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. RGDX: 58.00 )
RGDX' s 10-Year Price/Net Current Asset Value Range
Min: 2.69   Max: 58
Current: 58

2.69
58
Price/Tangible Book 7.70
RGDX's Price/Tangible Book is ranked lower than
68% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. RGDX: 7.70 )
RGDX' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 31.5
Current: 7.7

1.76
31.5
Price/Median PS Value 0.90
RGDX's Price/Median PS Value is ranked higher than
76% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. RGDX: 0.90 )
RGDX' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.62
Current: 0.9

0.62
1.62
Forward Rate of Return (Yacktman) -61.65
RGDX's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. RGDX: -61.65 )
RGDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 86.4   Max: 734.4
Current: -61.65

86.4
734.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Response Genetics, Inc. was formed as a Delaware corporation in September 1999. It is a life sciences company engaged in the research and development of innovative clinical diagnostic tests for cancer. The Company currently generates revenues mainly from sales of its ResponseDX diagnostic tests, which it launched in 2008 and by providing clinical trial testing services to pharmaceutical companies. It has developed technologies for the extraction of RNA from FFPE tissues which enable it to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics, and microarray platforms. In addition, its technologies permit gene profiling analysis of current clinical trials, most of which use the paraffin embedding technique for tissue specimen storage. The Company developed and patented extraction methodologies that allow reliable and consistent isolation of RNA and DNA from FFPE suitable for use in various types of analysis. The Company validated its methodology, which particularly addressed issues of recovery of RNA, accuracy, and precision. Further, its methodologies allow for rapid extraction of RNA with little or no DNA contamination, which makes it suitable for large-scale analysis. The Company developed ResponseDX in part by using its technology to extract genetic information from FFPE tumor specimens. Its technology provides gene expression information for each patient's tumor tissue specimen. It has developed assays for single genes comprising the ResponseDX panels for use in its CLIA lab. Assay development of these tests was done through appropriate validation procedures which determine the accuracy of each test. The Company offers ResponseDX test services nationwide. Its main sales include community based oncologists, pathologists, physician offices and hospitals. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its non-clinical testing processes. Its business is also subject to regulation under state and federal laws regarding environmental protection and hazardous substances control, such as the Federal Occupational Safety and Health Act, the Environmental Protection Act, and Toxic Substances Control Act.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide